HUE044812T2 - Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére - Google Patents

Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére

Info

Publication number
HUE044812T2
HUE044812T2 HUE04765616A HUE044812T2 HU E044812 T2 HUE044812 T2 HU E044812T2 HU E04765616 A HUE04765616 A HU E04765616A HU E044812 T2 HUE044812 T2 HU E044812T2
Authority
HU
Hungary
Prior art keywords
proteins
proline specific
specific endoproteases
hydrolyse
peptides
Prior art date
Application number
Other languages
English (en)
Inventor
Luppo Edens
Der Hoeven Robertus Van
Roos Andre De
Melissa Harvey
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of HUE044812T2 publication Critical patent/HUE044812T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
    • A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
    • A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
    • A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
HUE04765616 2003-09-23 2004-09-23 Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére HUE044812T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078012 2003-09-23
EP03078496 2003-11-06

Publications (1)

Publication Number Publication Date
HUE044812T2 true HUE044812T2 (hu) 2019-11-28

Family

ID=34379381

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE04765616 HUE044812T2 (hu) 2003-09-23 2004-09-23 Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére

Country Status (8)

Country Link
US (3) US8524225B2 (hu)
EP (1) EP1663298B1 (hu)
JP (2) JP5328100B2 (hu)
DK (1) DK1663298T3 (hu)
ES (1) ES2746173T3 (hu)
HU (1) HUE044812T2 (hu)
RU (1) RU2370279C2 (hu)
WO (1) WO2005027953A2 (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
MXPA04000480A (es) 2001-07-18 2004-07-23 Dsm Ip Assets Bv Proceso para la hidrolisis de proteinas lacteas.
EP1612558A1 (en) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
BRPI0707440A2 (pt) * 2006-02-02 2011-05-03 Dsm Ip Assets Bv produto alimentìcio compreendendo uma protease especìfica de prolina, sua preparação e seu uso para a degradação de peptìdeos de glúten alergêncios ou tóxicos
DK2402425T3 (da) * 2006-07-13 2021-07-05 Dsm Ip Assets Bv Forbedret brygningsproces
US20080169332A1 (en) 2007-01-11 2008-07-17 Shelton Frederick E Surgical stapling device with a curved cutting member
BRPI0808987A2 (pt) * 2007-03-16 2014-09-09 Univ Leland Stanford Junior Terapia combinatória de enzima para digestão de glúten dietético
BR122018009860B1 (pt) 2007-08-13 2021-05-04 Walter And Eliza Hall Institute Of Medical Research Produto produzido a partir do grão de cevada adequado para consumo de indivíduos portadores de doença celíaca e método para produzir grãos de cevada
US20100311643A1 (en) * 2007-09-11 2010-12-09 Dorian Bevec Use of glp-1 as a therapeutic agent
EP2229404A4 (en) * 2007-12-10 2011-03-09 Univ Leland Stanford Junior ENZYMATIC POLYTHERAPY FOR GASTRIC DIGESTION OF FOOD GLUTEN IN PATIENTS WITH CELIAC DISEASE
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
TW201000634A (en) * 2008-05-30 2010-01-01 Dsm Ip Assets Bv Proline-specific protease
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
BRPI1007378A2 (pt) 2009-01-06 2020-08-18 Curemark Llc composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
JP2012514604A (ja) 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011000773A1 (en) 2009-07-02 2011-01-06 Dsm Ip Assets B.V. Testing efficacy for celiac disease
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2531521B1 (en) * 2010-02-02 2017-09-06 Amano Enzyme USA., Ltd. Use of proteases for gluten intolerance
US20120244362A1 (en) 2011-03-22 2012-09-27 Pramanik Pranabes K Multi-layer sheet structure
EP2701733B1 (en) 2011-04-21 2019-04-03 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
US20140205587A1 (en) * 2011-06-17 2014-07-24 Alvine Pharmaceuticals, Inc. Proteases for Degrading Gluten
WO2013047082A1 (ja) * 2011-09-29 2013-04-04 天野エンザイム株式会社 外因性オピオイドペプチド分解酵素剤
JP6203743B2 (ja) 2011-12-06 2017-09-27 フオンダツイオーネ・イステイトウート・インスブリコ・デイ・リチエルカ・ペル・ラ・ビータ アクチノミセス・アクチノアロムルス（ＡＣＴＩＮＯＭＹＣＥＴＥＡＣＴＩＮＯＡＬＬＯＭＵＲＵＳ）由来の、酸性ｐＨにてグルテンペプチドおよびタンパク質を加水分解できる新規プロテアーゼ
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US20130344042A1 (en) * 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
BR102013003182B1 (pt) * 2013-02-08 2019-03-19 Vitor Carlos Veit Processo de fabricação de cerveja sem glúten
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
PL3004344T3 (pl) * 2013-05-31 2019-01-31 Dsm Ip Assets B.V. Immobilizowana endoproteaza swoista wobec proliny
UA122764C2 (uk) 2013-06-13 2021-01-06 Коммонвелт Сайнтіфік Енд Індастріел Рісерч Організейшн Ячмінь з дуже низьким вмістом гордеїнів та харчовий продукт на основі солоду
MY172939A (en) * 2013-07-12 2019-12-16 A2 Milk Co Ltd Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
EP2883458A1 (en) * 2013-12-11 2015-06-17 DSM IP Assets B.V. Medicament and method for treating innate immune response diseases
WO2015177152A1 (en) 2014-05-19 2015-11-26 Dsm Ip Assets B.V. Proline-specific endoprotease
WO2015177153A1 (en) 2014-05-19 2015-11-26 Dsm Ip Assets B.V. Proline-specific endoprotease
US10450554B2 (en) 2014-05-19 2019-10-22 Dsm Ip Assets B.V. Proline specific endoprotease
CA2951350C (en) 2014-07-01 2017-11-07 Dsm Ip Assets B.V. Low gluten yeast hydrolysates
JP6739767B2 (ja) * 2015-03-04 2020-08-12 学校法人日本大学 タンパク質シート及びタンパク質シートの製造方法
FR3035664B1 (fr) * 2015-04-29 2020-02-21 Malteries Soufflet Utilisation de cysteine endoprotease pour diminuer le trouble de boissons
JP6616198B2 (ja) * 2016-01-21 2019-12-04 オリエンタル酵母工業株式会社 パン類の品質改良剤及びパン類の製造方法
CN107814836A (zh) * 2017-12-01 2018-03-20 浙江熊猫乳业集团股份有限公司 一种生物活性多肽fpgpipns及其制备方法和应用
US20210315238A1 (en) * 2018-07-31 2021-10-14 Dupont Nutrition Biosciences Aps Proline specific endopeptidases
BR112021008095A2 (pt) * 2018-10-29 2021-08-03 The A2 Milk Company Limited análise de beta-caseína de leite e de produtos de leite
MX2022010250A (es) * 2020-02-19 2022-11-09 Perfect Day Inc Proteínas recombinantes hipoalergénicas de leche y composiciones que comprenden las mismas.
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7414128A (nl) 1973-10-31 1975-05-02 James Joseph Phelan Werkwijze voor de detoxificatie van gluten.
DD262999A1 (de) 1987-07-27 1988-12-21 Adw Ddr Verfahren zur herstellung eines diaetetikums fuer zoeliakie- und spruekranke
ES2197143T3 (es) 1991-07-24 2004-01-01 Novartis Ag Adn que codifica para prolilendopeptidasa.
US6251391B1 (en) 1999-10-01 2001-06-26 Klaire Laboratories, Inc. Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
AU1142001A (en) * 2000-10-19 2002-04-29 Dsm N.V. Protein hydrolysates
JP4119248B2 (ja) * 2000-12-07 2008-07-16 ディーエスエム アイピー アセッツ ビー．ブイ． カルボキシ末端プロリンを有するペプチドに富むタンパク質加水分解物
CA2431291C (en) * 2000-12-07 2010-09-21 Dsm N.V. Method for the prevention or reduction of haze in beverages
DK1224869T3 (da) 2001-01-12 2004-12-13 Campina Bv Fremgangsmåde til fremstilling af et glutenfrit peptidpræparat samt det således opnåede præparat
US7323327B2 (en) * 2001-02-23 2008-01-29 Dsm Ip Assets B.V. Genes encoding novel proteolytic enzymes
MXPA04000480A (es) * 2001-07-18 2004-07-23 Dsm Ip Assets Bv Proceso para la hidrolisis de proteinas lacteas.
NO318426B1 (no) 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
ATE505201T1 (de) * 2002-02-14 2011-04-15 Univ Leland Stanford Junior Enzymbehandlung von nahrungsmitteln für zöliakie- sprue
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
AU2003236689A1 (en) * 2002-06-04 2003-12-19 Dsm Ip Assets B.V. Protein hydrolysate rich in tripeptides
CN100519729C (zh) * 2002-06-07 2009-07-29 Dsmip资产有限公司 防止或降低饮料混浊的改进方法
AU2003264256A1 (en) * 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
EP1774014A2 (en) * 2004-07-12 2007-04-18 DSMIP Assets B.V. Blood pressure lowering oligopeptides
WO2006067163A2 (en) * 2004-12-22 2006-06-29 Dsm Ip Assets B.V. Blood pressure lowering oligopeptides in a single enzymatic step
US20140205587A1 (en) * 2011-06-17 2014-07-24 Alvine Pharmaceuticals, Inc. Proteases for Degrading Gluten

Also Published As

Publication number Publication date
EP1663298A2 (en) 2006-06-07
RU2006113586A (ru) 2006-08-10
EP1663298B1 (en) 2019-07-17
US20140206036A1 (en) 2014-07-24
JP2007505639A (ja) 2007-03-15
JP2011120601A (ja) 2011-06-23
JP5328100B2 (ja) 2013-10-30
ES2746173T3 (es) 2020-03-05
WO2005027953A2 (en) 2005-03-31
RU2370279C2 (ru) 2009-10-20
WO2005027953A3 (en) 2005-06-16
DK1663298T3 (da) 2019-10-14
US20070031399A1 (en) 2007-02-08
US20110142987A1 (en) 2011-06-16
US8524225B2 (en) 2013-09-03

Similar Documents

Publication Publication Date Title
HUE044812T2 (hu) Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
EP1616181A4 (en) POLYPEPTIDES RELATED TO NATRIURETIC PEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
HK1091894A1 (en) Prion protein binding materials and methods of use
EP1501514A4 (en) PROTEIN-KINASE MODULATORS AND METHODS OF USE
EP1660013A4 (en) BIOMATERIAL AND PROTEIN BIOCOACERVATES, METHODS OF MAKING AND USING THEM
EP1758617A4 (en) STABLE LIQUID AND LYOPHILIZED PROTEIN FORMULATIONS
EP1503795A4 (en) USE OF HOT SHOCK PROTEINS TO INCREASE THE EFFICACY OF ANTIBODY THERAPEUTICS
AU2003211093A8 (en) Inhibitors of rgs proteins
EP1622928A4 (en) INSERTION OF FURINE PROTEASE CLEAVAGE SITES IN MEMBRANE PROTEINS AND USES THEREOF
EP1578917A4 (en) MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
EP1696943A4 (en) PEPTIDES DIASTEREOMERS USEFUL AS INHIBITORS OF MEMBRANE PROTEIN ASSEMBLY
SI1616007T1 (sl) Inhibitor proteini proteaze in njih uporaba
AU2003282338A8 (en) Determination of protein function
AU2003246614A8 (en) Novel use of lipopeptide preparations
HK1089099A1 (en) Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
EP1560843A4 (en) NEW VARIANTS OF RANKL PROTEIN
AU2003301692A8 (en) Essential dna enclosed proteins of drosphophilia melanogaster
AU2003282159A8 (en) Chimeric recombinant protein and in vitro diagnosis of hiv
AU2003260487A8 (en) Novel pancortin-pablo protein interactions and methods of use thereof
EP1541677A4 (en) NEW PROTEINS AND USE THEREOF
EP1577322A4 (en) NEW PROTEINS AND THEIR USE
EP1549951A4 (en) SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF
EP1576168A4 (en) THERAPEUTIC POLYPEPTIDES, THESE CODING NUCLEIC ACIDS AND METHOD OF USE
EP1730278A4 (en) PROCESS FOR PREPARING AND PURIFYING RECOMBINANT PROTEINS
AU2002364105A8 (en) Compositions and methods relating to endometrial specific genes and proteins